In patients with type 2 diabetes and chronic kidney disease, sodium-glucose cotransporter-2 inhibitors lower the rate of hospitalization for heart failure by 40% compared to placebo and are more...
Mechanism
Synthesis from 1 study
SGLT2 inhibitors make the kidneys flush out more salt and water, which lowers blood volume and pressure on the heart. This reduces strain on the heart and prevents fluid buildup that leads to heart failure. Other drugs work differently, but none reduce this pressure as effectively.
Most probable mechanism
By blocking sugar and salt reabsorption in the kidneys, the drug causes more water and salt to be flushed out, which lowers blood volume and pressure on the heart. This also reduces high pressure inside the kidney filters, protecting the kidneys and preventing fluid buildup that strains the heart.
Sodium-glucose cotransporter 2 in the proximal renal tubule is inhibited, reducing reabsorption of glucose and sodium
Increased sodium delivery to the macula densa activates tubuloglomerular feedback, reducing afferent arteriolar pressure and intraglomerular hypertension
Reduced intraglomerular pressure decreases glomerular hyperfiltration, limiting podocyte injury and albuminuria
Osmotic diuresis and natriuresis reduce plasma volume and venous return, lowering cardiac filling pressures and preload
Reduced systemic glucose levels and oxidative stress improve mitochondrial efficiency and decrease reactive oxygen species production in cardiac and renal tissues
Lower cardiac preload and improved myocardial energetics reduce ventricular wall stress and diastolic stiffness, preventing fluid accumulation and heart failure decompensation
Less supported by current evidence, but not ruled out
Blocking a hormone receptor in the heart and kidneys reduces scarring and inflammation, making the heart muscle more flexible and the kidney filters less leaky.
Mineralocorticoid receptors in cardiac fibroblasts and renal tubular cells are antagonized
Inhibition of NF-κB and other pro-inflammatory pathways reduces cytokine production and macrophage infiltration
Downregulation of TGF-β and collagen synthesis decreases extracellular matrix deposition in myocardium and glomeruli
Reduced fibrosis improves myocardial compliance and glomerular barrier integrity, lowering heart failure risk
Activating a receptor on blood vessels and heart cells improves blood flow and energy use in the heart, reducing damage and death of heart tissue.
GLP-1 receptors on endothelial cells and cardiomyocytes are activated, increasing cAMP and protein kinase A signaling
Nitric oxide production increases, improving vascular tone and reducing endothelial dysfunction
Suppression of TNF-α and IL-6 reduces systemic inflammation and macrophage activation in vascular and cardiac tissues
Prolonged tissue exposure due to resistance to degradation enhances sustained cardioprotective signaling
Improved myocardial energetics and reduced apoptosis lower the incidence of heart failure and cardiovascular death
Evidence from Studies
Supporting (1)
Community contributions welcome
Contradicting (0)
Community contributions welcome
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.